An accurate, fast, and miniaturized glucose sensor for closed-loop diabetes management
An accurate, fast, and miniaturized glucose sensor for closed-loop diabetes management
批准号:
9898653
负责人:
William Van Antwerp
金额:
$78.69万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-08-31
关键词:
AdoptionAffectAgreementAnimal TestingAnimalsArtificial PancreasBiocompatible MaterialsBiotechnologyBloodBusinessesCalibrationCarbohydratesCellular PhoneChronicDataData AnalysesDevelopmentDevicesDiabetes MellitusDiseaseElectric CapacitanceElectronicsEmergency department visitEngineeringEnvironmentExcisionFamily suidaeFeedbackForeign BodiesForeign-Body ReactionFundingGeometryGlucoseGoalsGrainHealthHealth ProfessionalHumanHypoglycemiaImplantIn VitroInfectionInsulinInsulin Infusion SystemsInsurance CoverageKineticsLongevityMeasurementMeasuresMetabolismMicroelectrodesModelingMorbidity - disease rateNeedlesNoiseOperative Surgical ProceduresPatientsPhasePopulationPumpRattusReaction TimeReaderReadingReportingResearchResearch PersonnelRiceSafetySeasonsSemiconductorsSiteSkinSleepSmall Business Innovation Research GrantSpeedSubcutaneous TissueSurveysSystemTechnologyTestingThinnessTimeTissuesTrainingUnited States National Institutes of HealthVascularizationWireless TechnologyWorkblood glucose regulationcloud basedcommercializationcostdata visualizationdesigndiabetes managementdiabeticexperiencefirst-in-humanflexibilityglucose monitorglucose sensorglycemic controlimprovedinnovationirritationmicrosystemsmillimeterminiaturizemonitoring devicemortalitynovelquality assuranceresponsesensorsensor technologysmart watchsubcutaneoussuccessuser-friendly
中文摘要
项目总结
这个项目的长期目标是开发一种低成本、用户友好和准确的血糖传感解决方案
具有多传感器可靠性,能够在人工胰腺中使用闭环式胰岛素给药。系统
由于体积小,传感器和相关电子设备非常接近,所以传感器的动态响应速度很快。
小型化电极,具有低电容、薄而灵活的外形,可更好地与
周围组织和局部血管形成。这可以实现自动闭环血糖控制,而不需要
进餐通告和碳水化合物计数。该系统还具有出色的降糖准确度
小到体积小,与周围组织更好地融合(研究策略中有详细信息)。
IMS已经开发出一种新颖的、小型化的(比米粒还小)、完全无线的、极低成本的
仅由单个半导体器件(微系统)组成的葡萄糖传感器。这台设备可以感知
一种新颖的微电子设计和集成片上电化学传感器。这
该装置使用专有的插入器注射到皮下组织中,并无线传输葡萄糖
将数据传输到外部可穿戴式传送器,该传送器将数据转发到智能手机,以实现数据可视化和
基于云的数据处理,提供实时反馈。在加州理工学院、美国国立卫生研究院和美国国家科学基金会的资助下,我们有
在体外、在大鼠身上和在猪模型中的中展示了传感器的功能,超过1个月的。我们的结果
表明传感器非常准确(最重要的量程<;210 mg/dl的MARD=6.2%),并且可以
与目前的经皮CGM产品相比,工作时间更长(>;1个月)。此外,
该装置是用户可插入和可拆卸的,因此不需要在
其他无线CGM设备(如Everense by Senseonics)要求的医生办公室。
我们在这项提议中的目标是开发一个版本的我们的血糖传感平台,可以用于
首例人类测试。拟议中的新微系统将安装在较小(29英寸)的针头上,使用
弹簧加载插入器,可实现安全、准确的插入。它将连接到一个小磁盘上,以便安全地移除
在传感器使用寿命之后(例如,在>;1个月之后)。该设备将使用三片上的血糖测量
传感器连接到提高了读数的可靠性。该传感平台将在猪模型上进行测试,因为它
与人的皮肤和新陈代谢非常匹配。
这项研究具有意义,因为它将使类中最小的(29个可插入的)能够在工厂校准,
用户可插入和可拆卸,CGM可长时间工作(>;30天),提供冗余可靠性
血糖传感和快速响应,均可实现安全准确的闭环血糖控制
人工胰腺。此外,由于半导体的设计,该系统提供了最低的商品成本
技术
Team项目包括来自加州理工学院的核心技术的原始发明者(纳扎里博士、拉赫曼博士、拉赫曼先生)。
Sencan),经验丰富且受人尊敬的葡萄糖传感器技术研究员(Bill Van Antwerp),实验性
外科和生物材料专家(加州大学欧文分校的乔纳森·拉基博士)和商业化专家(彼得先生
来自MiniMed、Therasense和OptiScan的规则)。该公司正在IVD Technologies Inc.内部工作,这是一家ISO
经过认证,FDA根据设施租赁协议注册的生物技术公司。
英文摘要
PROJECT SUMMARY
The long term goal of this project is to develop a low-cost, user-friendly, and accurate glucose sensing solution
with multisensor reliability to enable the use of closed-loop insulin delivery in an artificial pancreas. The system
demonstrates fast sensor kinetics owing to small size, close proximity of sensor and related electronics,
miniaturized electrodes with low capacitance, and thin and flexible profile leading to better integration with the
surrounding tissue and local vascularization. This can enable automatic closed-loop glucose control without
meal announcements and carbohydrate counting. The system also has excellent hypoglycemia accuracy due
to small size and better integration with surrounding tissue (details available in research strategy).
IMS has developed a novel, miniaturized (smaller than rice grain), completely wireless, and extremely low-cost
glucose sensor that consists solely of a single semiconductor device (microsystem). This device can sense
glucose owing to a novel microelectronics design and an integrated on-chip electrochemical sensor. This
device is injected in subcutaneous tissue using a proprietary inserter and wirelessly communicates the glucose
data to an external wearable transmitter which relays it to a smartphone to enable data visualization and
cloud-based data handling to provide real-time feedback. With help of Caltech, NIH, and NSF funding, we have
demonstrated sensor functionality in-vitro, in rats, and in porcine model for more than 1 month. Our results
indicate the sensor is very accurate (MARD=6.2% for <210 mg/dl which is the most important range), and can
work for longer time (> 1 month) when compared to current transcutaneous CGM products. Moreover, the
device is user-insertable and removable and hence eliminates the requirement of surgical procedures at
doctor’s office as required by other wireless CGM devices (e.g. eversense by Senseonics).
Our objective in this proposal is to develop a version of our glucose sensing platform that can be used for
First-In-Human testing. The proposed new microsystem will fit in a smaller (29 gauge) needle using a
spring-loaded inserter to enable safe and accurate insertion. It will be attached to a small disk for safe removal
of the sensor after its lifetime (e.g. after > 1 month). The device will measure glucose using three on-chip
sensors to increase the reliability of the readout. The sensing platform will be tested in porcine model as it
matches well with human skin and metabolism.
This research is significant as it will enable the smallest in class (29 gauge insertable) factory-calibrated,
user-insertable and removable, CGM that can work for a long time (>30 days), provide reliability of redundant
glucose sensing, and fast response that can all enable safe and accurate closed-loop glucose control in an
artificial pancreas. Also, the system offers lowest cost of goods by design owing to the semiconductor
technology.
The project team includes original inventors of the core technology from Caltech (Dr. Nazari, Dr. Rahman, Mr.
Sencan), seasoned and respected researcher in Glucose sensor technology (Bill Van Antwerp), experimental
surgery and biomaterials expert (Dr. Jonathan Lakey of UC Irvine) and commercialization expert (Mr. Peter
Rule from MiniMed, Therasense, and OptiScan). The company is working within IVD Technologies Inc., an ISO
certified, FDA registered biotechnology company under a facilities rental agreement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An accurate, fast, and miniaturized glucose sensor for closed-loop diabetes management
-
批准号:10021644
-
项目类别:
-
资助金额:$70.58万
-
财政年份:2016
-
负责人:William Van Antwerp
-
依托单位:
海外基金